<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36736">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799421</url>
  </required_header>
  <id_info>
    <org_study_id>NEURISK</org_study_id>
    <nct_id>NCT01799421</nct_id>
  </id_info>
  <brief_title>Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy</brief_title>
  <acronym>NEURISK</acronym>
  <official_title>Predictive Models of Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para el Fomento de la Investigación y el Desarrollo Integral de la Oncología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para el Fomento de la Investigación y el Desarrollo Integral de la Oncología</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify prognostic factors and to develop predictive models
      of risk of febrile neutropenia and neutropenia grade 3/4 in patients with solid tumors
      receiving chemotherapy with schemas that have an inherent risk of febrile neutropenia of
      10-20%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Identify predictive models about the risk of febrile neutropenia and neutropenia grade 3/4 in patients with non-hematologic cancer</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze costs to treat febrile neutropenia and neutropenia grade 3/4</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the risk of mortality due to febrile neutropenia and neutropenia grade 3/4 during the chemotherapy treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A Cox proportional hazards regression will be used to evaluate the risk of mortality due to febrile neutropenia and neutropenia grade 3/4 during chemotherapy treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate impact of febrile neutropenia and neutropenia grade 3/4 in treatment compliance</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The impact of febrile neutropenia and neutropenia grade 3/4 in treatment compliance (yes/no) will be evaluated using a chi-square test.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Non-hematologic Cancer</condition>
  <arm_group>
    <arm_group_label>Non-haematologic cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-hematologic cancer that will start chemotherapy treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 18 years

          -  Histologically confirmed solid tumor.

          -  Subjects who have not received chemotherapy and / or radiotherapy in the last 3
             months.

          -  Subject to initiate a chemotherapy (ie, cycle 1, day 1)

          -  The chemotherapy regimen should have an inherent risk of febrile neutropenia of
             10-20%.

          -  Planning a minimum of 3 cycles chemotherapy.

          -  Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥
             100.000/mm3; neutrophils ≥ 1,500 / mm3.

          -  Adequate hepatic and renal function, defined by: bilirubin &lt;1.5 times the normal
             value, ALT and AST &lt;3 times the normal range (both can be elevated up to 5 times the
             normal value in patients with known liver metastases); creatinine &lt;1.5 times upper
             normal value

          -  ECOG ≤ 2.

          -  Informed consent

        Exclusion Criteria:

          -  Patients under treatment with an investigational treatment.

          -  Active infection in the last 72 h before starting chemotherapy.

          -  Indication of chemotherapy dose intensity or chemotherapy included in the risk rating
             of febrile neutropenia &lt;10% or &gt;20%.

          -  Patients with concomitant chemoradiotherapy.

          -  Patients being treated with biological drugs in monotherapy.

          -  Any other condition causing neutropenia.

          -  History of bone marrow transplant or stem cells.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. José Muñoz Langa, Medicine</last_name>
    <phone>+34 616 339 731</phone>
    <email>munyoz_joslan@gva.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Basurto</city>
        <state>Bilbao</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purificación Martínez del Prado, Medicine</last_name>
      <phone>+34 944006367</phone>
      <email>purificacion.martinezdelprado@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Purificación Martínez del Prado, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Encarnación Jiménez Orozco, Medicine</last_name>
      <phone>+34 956 032 244</phone>
      <email>oncologiahj.jerez.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Encarnación Jiménez Orozco, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Donosti</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipuzcua</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria José Lecumberri, Medicine</last_name>
      <phone>+34 848 422 576</phone>
      <email>mj.lecumberri.biurrun@navarra.es</email>
    </contact>
    <investigator>
      <last_name>Maria José Lecumberri, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martín Lázaro Quintela, Medicine</last_name>
      <phone>+34 986 21 98 83</phone>
      <email>martin.lázaro.quintela@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Martín Lázaro Quintela, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera</name>
      <address>
        <city>A coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Miguel Antón Aparicio, Medicine</last_name>
      <phone>+34 657 669 485</phone>
      <email>luis.anton.aparicio@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Luis Miguel Antón Aparicio, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose María García Bueno, Medicine</last_name>
      <phone>+34 967597153</phone>
      <email>jmgb1967@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>José Maria García Bueno, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Ángeles, Medicine</last_name>
      <phone>+34 607209424</phone>
      <email>crisonco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Ángeles, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ruiz Echarri, Medicine</last_name>
      <phone>+34 627683223</phone>
      <email>mruizecharri.bcn@quiron.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Ruiz Echarri, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Borrega, Medicine</last_name>
      <phone>+34 927256406</phone>
      <email>pablo.borregag@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Borrega, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Brunet, Medicine</last_name>
      <phone>+34 972 22 58 28</phone>
      <email>jbrunet@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Joan Brunet, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Ramón Delgado, Medicine</last_name>
      <phone>+34 958020173</phone>
      <email>juanr.delgado.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Juan Ramón Delgado, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Lugo</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Campos Balea, Medicine</last_name>
      <phone>+34 982 296 459</phone>
      <email>bcamposbalea@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Begoña Campos Balea, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseger</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Carmona, Medicine</last_name>
      <phone>+34 968 36 09 00</phone>
      <phone_ext>3807</phone_ext>
      <email>alberto.carmonabayonas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alberto Carmona, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús García Mata, Medicine</last_name>
      <phone>+34 988 385 471</phone>
      <email>jesus.garcia.mata@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Jesús García Mata, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Valení, Medicine</last_name>
      <phone>+34 667842624</phone>
      <email>vvalenti@xarxatecla.cat</email>
    </contact>
    <investigator>
      <last_name>Vicente Valentí, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Cruz, Medicine</last_name>
      <phone>+34 925269179</phone>
      <email>mcruz@sescam.jccm.es</email>
    </contact>
    <investigator>
      <last_name>Miguel Angel Cruz, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Muñoz Langa, Medicine</last_name>
      <phone>+34 616 339 731</phone>
      <email>munyoz_joslan@gva.es</email>
    </contact>
    <investigator>
      <last_name>José Muñoz Langa, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Campos, Medicine</last_name>
      <phone>+34 96 398 77 00</phone>
      <email>jmcamposcervera@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Juan Manuel Campos, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael López Castro, Medicine</last_name>
      <phone>+34 646 121 566</phone>
      <email>rafalopezcastro@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael López Castro, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 8, 2013</lastchanged_date>
  <firstreceived_date>February 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
